Clopidogrel Tablet, Film Coated
Product Images NDC 68071-4138

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68071-4138). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 4138 03 T70)

Label for NuCare Pharmaceuticals Inc. Clopidogrel 75 mg film-coated tablets, prescription only. The label indicates 30 tablets per package with directions to take every 4 hours, and includes warnings to keep out of reach of children and to store at controlled temperature 68-77°F. The product number is R1500030 with NDC 68071-4138-3.*

FDA Label Image

Figure-03a.jpg (Figure 03a)

A forest plot chart displaying the hazard ratios with 95% confidence intervals comparing Clopidogrel to placebo across various subgroups such as age, gender, race, elevated cardiac enzyme status, diabetes, previous myocardial infarction, and previous stroke. The chart visually represents the relative favoring of Clopidogrel or placebo based on subgroup analysis data.*

FDA Label Image

Figure-03b.jpg (Figure 03b)

A forest plot chart displaying hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various subgroups, including Heparin/LMWH, Aspirin dosage, GPIIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use. The chart shows relative favorability between Clopidogrel and placebo with subgroup sample sizes and event percentages.*

FDA Label Image

Figure-06.jpg (Figure 06)

A forest plot displaying subgroup analyses comparing Clopidogrel to placebo across various categories including gender, age, time since onset, systolic blood pressure, heart rate, and fibrinolytic agent usage. The plot shows odds ratios with 99% confidence intervals for each subgroup, visually indicating which treatment is favored.*

FDA Label Image

Figure-08.jpg (Figure 08)

A forest plot comparing Clopidogrel and Aspirin across qualifying conditions including Stroke, MI, PAD, and Overall. The plot shows hazard ratios with 95% confidence intervals for each condition, indicating relative favorability towards Clopidogrel or Aspirin based on the data points and confidence bars along the horizontal axis.*

FDA Label Image

Structural Formula For Clopidogrel Bisulfate (Image 01)

Chemical structure of clopidogrel sulfate, showing its molecular components including a thienopyridine ring, an ester group, and a chlorophenyl group, associated with sulfuric acid (H2SO4).*

FDA Label Image

Figure 1 (Image 02)

A horizontal error bar chart showing the effect of coadministered proton pump inhibitors (PPIs) on the active metabolite AUC of clopidogrel. The PPIs listed are Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The x-axis represents the change relative to clopidogrel administered alone, ranging from 0.4 to 1.4, with each PPI showing a mean and 90% confidence interval for its impact on clopidogrel metabolism.*

FDA Label Image

Figure 2 (Image 03)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. The graph compares two groups: placebo (+ aspirin) and clopidogrel (+ aspirin), with clopidogrel showing a lower event rate. A significant p-value of 0.00009 is displayed, indicating statistical difference between groups.*

FDA Label Image

Figure 4 (Image 05)

A Kaplan-Meier survival curve showing the percentage of deaths before first discharge over 28 days since randomization. The graph compares Clopidogrel with placebo, noting deaths and a 7% proportional risk reduction (p = 0.03) in the Clopidogrel group.*

FDA Label Image

Figure 5 (Image 06)

A line graph comparing percentages of patients with death, re-infarction, or stroke before first discharge over days since randomization (up to 28 days). Two curves represent Placebo (10.1% event rate) and Clopidogrel (9.2% event rate), showing a 9% proportional risk reduction (p = 0.002) favoring Clopidogrel.*

FDA Label Image

Figure 8 (Image 09)

A line graph comparing cumulative event rates (%) of fatal or non-fatal vascular events between aspirin and clopidogrel over months of follow-up up to 36 months. The vertical axis represents cumulative event rate percentage, and the horizontal axis represents months of follow-up. Both lines trend upward, with aspirin slightly higher than clopidogrel, and a p-value of 0.045 indicated on the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.